Advanced search
Publication Cover
Bioanalysis Volume 12, 2020 - Issue 16
Submit an article Journal homepage
265
Views
0
CrossRef citations to date
0
Altmetric
Research Article

Quantitation of 2-Hydroxyglutarate in Human Plasma Via LC–MS/MS Using a Surrogate Analyte Approach

Feng Yin1 Agios Pharmaceuticals, Inc., 88 Sidney Street, Cambridge, MA02139, USACorrespondence[email protected]
,
Yonghua Ling2 PPD Inc., 3230 Deming Way, Middleton, WI53562, USA
,
Jennifer Keller2 PPD Inc., 3230 Deming Way, Middleton, WI53562, USA
,
Dennis Kraus2 PPD Inc., 3230 Deming Way, Middleton, WI53562, USA
,
Rohini Narayanaswamy1 Agios Pharmaceuticals, Inc., 88 Sidney Street, Cambridge, MA02139, USA
,
Heidi Mangus1 Agios Pharmaceuticals, Inc., 88 Sidney Street, Cambridge, MA02139, USA
,
Fumin Li2 PPD Inc., 3230 Deming Way, Middleton, WI53562, USA
,
Hua Yang1 Agios Pharmaceuticals, Inc., 88 Sidney Street, Cambridge, MA02139, USA
&
Guowen Liu1 Agios Pharmaceuticals, Inc., 88 Sidney Street, Cambridge, MA02139, USA
 show all
Pages 1149-1159 | Received 09 May 2020, Accepted 15 Jul 2020, Published online: 06 Aug 2020

References

  • Geisbrecht B , GouldS. The human PICD gene encodes a cytoplasmic and peroxisomal NADP(+)-dependent isocitrate dehydrogenase. J. Biol. Chem.274(43), 30527–30533 (1999).
  • Wang F , TravinsJ , DeLa Barre Bet al. Targeted inhibition of mutant IDH2 in leukemia cells induces cellular differentiation. Science340(6132), 622–626 (2013).
  • Hamamoto T , MunakataR , TajiriRet al. Localization of cytosolic NADP-dependent isocitrate dehydrogenase in the peroxisomes of rat liver cells: biochemical and immunocytochemical studies. J. Histochem. Cytochem.49(9), 1123–1131 (2001).
  • Saha SK , ParachoniakCA , GhantaKSet al. Mutant IDH inhibits HNF-4α to block hepatocyte differentiation and promote biliary cancer. Nature513(7516), 110–114 (2014).
  • Lu C , WardPS , KapoorGSet al. IDH mutation impairs histone demethylation and results in a block to cell differentiation. Nature483(7390), 474–478 (2012).
  • Xu W , YangH , LiuYet al. Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of α-ketoglutarate-dependent dioxygenases. Cancer Cell19(1), 17–30 (2011).
  • Hollenbach PW , NguyenAN , BradyHet al. A comparison of azacitidine and decitabine activities in acute myeloid leukemia cell lines. PLoS ONE5(2), e9001 (2010).
  • Dang L , WhiteDW , GrossSet al. Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Nature462(7274), 739–744 (2009).
  • Gross S , CairnsRA , MindenMDet al. Cancer-associated metabolite 2-hydroxyglutarate accumulates in acute myelogenous leukemia with isocitrate dehydrogenase 1 and 2 mutations. J. Exp. Med.207(2), 339–344 (2010).
  • Ward PS , PatelJ , WiseDRet al. The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate. Cancer Cell17(3), 225–234 (2010).
  • Fathi AT , SadrzadehH , BorgerDRet al. Prospective serial evaluation of 2-hydroxyglutarate, during treatment of newly diagnosed acute myeloid leukemia, to assess disease activity and therapeutic response. Blood120(23), 4649–4652 (2012).
  • Popovici-Muller J , LemieuxRM , ArtinEet al. Discovery of AG-120 (Ivosidenib): a first in class mutant IDH1 inhibitor for the treatment of IDH1 mutant cancers. ACS Med. Chem. Lett.9(4), 300–305 (2018).
  • McGehee E , RakhejaD , OliverDet al. The importance of plasma D-2HG measurement in screening for IDH mutations in acute myeloid leukaemia. Br. J. Haematol.173(2), 314–328 (2016).
  • Fan B , MellinghoffI , WenPet al. Clinical pharmacokinetics and pharmacodynamics of ivosidenib, an oral, targeted inhibitor of mutant IDH1, in patients with advanced solid tumors. Invest. New Drug38(2), 433–444 (2020).
  • Delahousse J , VerlingueL , BroutinSet al. Circulating oncometabolite D-2-hydroxyglutarate enantiomer is a surrogate marker of isocitrate dehydrogenase mutated intrahepatic cholangiocarcinomas. Eur. J. Cancer90, 83–91 (2018).
  • US FDA. Biomarker Qualification: Evidentiary Framework (2018). https://www.fda.gov/media/122319/download
  • Jones BR , SchultzGA , EcksteinJAet al. Surrogate matrix and surrogate analyte approaches for definitive quantitation of endogenous biomolecules. Bioanalysis4(19), 2343–2356 (2012).
  • Chen J , TabatabaeiA , ZookDet al. A surrogate analyte-based liquid chromatography–tandem mass spectrometry method for the determination of endogenous cyclic nucleotides in rat brain. J. Pharm. Biomed. Anal.146, 361–368 (2017).
  • Sidhu R , JiangH , FarhatNYet al. A validated LC–MS/MS assay for quantification of 24(S)-hydroxycholesterol in plasma and cerebrospinal fluid. J. Lipid Res.56(6), 1222–1233 (2015).
  • Yin F , KellerJ , KrausDet al. A double surrogate approach for the quantitation of 2-hydroxyglutarate – an oncometabolite in human brain tumors via LC–MS/MS. J. Pharm. Biomed. Anal.179, 112916 (2020).
  • US FDA. Bioanalytical Method Validation Guidance for Industry (2018). https://www.fda.gov/media/70858/download

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.